Upgrade to SI Premium - Free Trial

Guggenheim Reiterates Buy on Teva Pharma (TEVA) Following AGN Deal

August 15, 2016 7:21 AM
Guggenheim reiterated a Buy rating and $80.00 price target on Teva Pharma (NYSE: TEVA) following the close of the company's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles